As a result, GBM cells treated with Cu/DPA showed decreased transcriptional levels of TGF-β1 and TGF-β2 compared with cells treated with CuSO4 or Cu/TETA, as determined by RT-PCR (Figure 4A). The gene discussed is TGFB1; the disease is glioblastoma.